Insights - Sorrento Therapeutics (SRNE) has sold lead drug candidate Cynviloq to NantPharma, founded by healthcare entrepreneur & SRNE’s largest investor, Patrick Soon-Shiong, and a subsidiary of partner NantWorks. Sorrento … Continue Reading
Read nowInsights - An independent advisory committee to the U.S. FDA voted in favor of approving Vertex Pharmaceuticals’ (VRTX) new treatment for Cystic Fibrosis, Orkambi, on Tuesday afternoon. The … Continue Reading
Read nowInsights - Alexion Pharmaceuticals (ALXN) is buying fellow ultra orphan drug developer Synageva (GEVA) for $8.4 billion. Alexion will pay $115 in cash and 0.6581 Alexion shares … Continue Reading
Read nowInsights - The FDA just doesn’t want to meet with AcelRx Pharmaceuticals (ACRX). Reported alongside the company’s first quarter financial update, AcelRx’s request for a Type B … Continue Reading
Read nowInsights - Gilead Sciences (GILD) blew past analyst expectations in the first quarter, reporting $7.6 billion in total revenue vs. consensus estimates of $6.9 billion. More important, the company reported an impressive … Continue Reading
Read nowResearch - It’s happened– the first high-profile failure from the re-emerging cohort of publicly traded gene therapy developers. Celladon (CLDN) reported on Sunday that MYDICAR, the company’s … Continue Reading
Read nowInsights - In a deal valued at $1.275 billion all-in, AstraZeneca (AZN) will partner with Innate Pharma (IPH.PA) for the development of IPH2201, Innate’s anti-NKG2A antibody. For … Continue Reading
Read now
